<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307033</url>
  </required_header>
  <id_info>
    <org_study_id>0954A-351</org_study_id>
    <nct_id>NCT01307033</nct_id>
  </id_info>
  <brief_title>A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)</brief_title>
  <official_title>A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential
      hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2011</start_date>
  <completion_date type="Actual">December 4, 2012</completion_date>
  <primary_completion_date type="Actual">December 4, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8</measure>
    <time_frame>Baseline and Week 8 (End of Double-blind Period)</time_frame>
    <description>Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8</measure>
    <time_frame>Baseline and Week 8 (End of Double-blind Period)</time_frame>
    <description>Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>MK-954H (L50/H12.5)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0954A (L100/H12.5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0954A</intervention_name>
    <description>Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily</description>
    <arm_group_label>MK-0954A (L100/H12.5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-954H</intervention_name>
    <description>Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily</description>
    <arm_group_label>MK-954H (L50/H12.5)</arm_group_label>
    <other_name>Preminent®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-0954A</intervention_name>
    <description>Placebo tablet to match MK-0954A, once daily</description>
    <arm_group_label>MK-954H (L50/H12.5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-954H</intervention_name>
    <description>Placebo tablet to match MK-954H, once daily</description>
    <arm_group_label>MK-0954A (L100/H12.5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participant has a diagnosis of essential hypertension.

          -  Participant is being treated with a single, or dual combination treatment for
             hypertension and will be able to discontinue the prior antihypertensive medication.

          -  Participant has a mean trough SiDBP of &gt;=90mmHg and &lt; 110mmHg.

          -  Participant has a mean trough SiSBP of &gt;=140mmHg and &lt; 200mmHg.

          -  Participant has no clinically significant abnormality at screening visit.

        Exclusion criteria:

          -  Participant is currently taking &gt; 2 antihypertensive medications.

          -  Participant has a history of significant multiple and/or severe allergies to
             ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e.,
             sulfonamide-containing &quot;chlortalidone&quot; medicines).

          -  Participant is, at the time of signing informed consent, a user of recreational or
             illicit drugs or has had a recent history within the last year of drug or alcohol
             abuse or dependence.

          -  Participant is pregnant or breastfeeding, or expecting to conceive or the pregnancy
             test is positive at screening visit.

          -  Participant is currently participating or has participated in a study with an
             investigational compound or device within 30 days of signing informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Fujimoto G, Azuma K, Shirakawa M, Hanson ME, Fujita KP. Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. Hypertens Res. 2014 Dec;37(12):1042-9. doi: 10.1038/hr.2014.114. Epub 2014 Jul 3. Erratum in: Hypertens Res. 2014 Dec;37(12):1088.</citation>
    <PMID>24990091</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <results_first_submitted>November 14, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2014</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>Uncontrolled hypertension</keyword>
  <keyword>Antihypertensive agents</keyword>
  <keyword>Blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-0954H (L50/H12.5) Double Blind Period (Period 1)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5)</description>
        </group>
        <group group_id="P2">
          <title>MK-0954A (L100/H12.5) Double Blind Period (Period 1)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5)</description>
        </group>
        <group group_id="P3">
          <title>L50/H12.5→L100/H12.5 Open Label (Period 2)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)</description>
        </group>
        <group group_id="P4">
          <title>L100/H12.5→L100/H12.5 Open Label (Period 2)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>8-week Double-blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Blood Pressure Withdrawal Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Potassium Withdrawal Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>44-week Open-label Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="131"/>
                <participants group_id="P4" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Blood Pressure Withdrawal Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Potassium Withdrawal Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-0954H (L50/H12.5)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)</description>
        </group>
        <group group_id="B2">
          <title>MK-0954A (L100/H12.5)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="278"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="10.7"/>
                    <measurement group_id="B2" value="57.8" spread="10.8"/>
                    <measurement group_id="B3" value="57.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8</title>
        <description>Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.</description>
        <time_frame>Baseline and Week 8 (End of Double-blind Period)</time_frame>
        <population>Full Analysis Set (FAS) population: defined as all randomized participants who received at least one dose of study treatment, had at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of study treatment, and had baseline data for those analyses that required baseline data</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0954H (L50/H12.5)</title>
            <description>One combination tablet daily for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5).</description>
          </group>
          <group group_id="O2">
            <title>MK-0954A (L100/H12.5)</title>
            <description>One combination tablet daily for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8</title>
          <description>Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.</description>
          <population>Full Analysis Set (FAS) population: defined as all randomized participants who received at least one dose of study treatment, had at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of study treatment, and had baseline data for those analyses that required baseline data</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="0.7" lower_limit="-6.6" upper_limit="-3.9"/>
                    <measurement group_id="O2" value="-5.0" spread="0.7" lower_limit="-6.4" upper_limit="-3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8</title>
        <description>Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.</description>
        <time_frame>Baseline and Week 8 (End of Double-blind Period)</time_frame>
        <population>Full Analysis Set (FAS) population: defined as all randomized participants who received at least one dose of study treatment, had at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of study treatment, and had baseline data for those analyses that required baseline data</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0954H (L50/H12.5)</title>
            <description>One combination tablet daily for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5)</description>
          </group>
          <group group_id="O2">
            <title>MK-0954A (L100/H12.5)</title>
            <description>One combination tablet daily for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8</title>
          <description>Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.</description>
          <population>Full Analysis Set (FAS) population: defined as all randomized participants who received at least one dose of study treatment, had at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of study treatment, and had baseline data for those analyses that required baseline data</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" lower_limit="-8.2" upper_limit="-4.3"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-10.5" upper_limit="-6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)</title>
        <time_frame>Up to 52 weeks</time_frame>
        <population>All-Patients-as-Treated (APaT) Population, which consists of all randomized patients who received at least one dose of MK-0954A. The L100/H12.5 (L50/H12.5) arm only includes data from extension period (44 weeks); L100/H12.5→L100/H12.5 Open Label arm includes data from entire study period (52 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>L50/H12.5→L100/H12.5 Open Label (Period 2)</title>
            <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)</description>
          </group>
          <group group_id="O2">
            <title>L100/H12.5→L100/H12.5 Open Label (Period 2)</title>
            <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)</title>
          <population>All-Patients-as-Treated (APaT) Population, which consists of all randomized patients who received at least one dose of MK-0954A. The L100/H12.5 (L50/H12.5) arm only includes data from extension period (44 weeks); L100/H12.5→L100/H12.5 Open Label arm includes data from entire study period (52 weeks).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0"/>
                    <measurement group_id="O2" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>All-Patients-as-Treated (APaT) Population defined as all randomized participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-0954H (L50/H12.5) Double Blind Period (Period 1)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5)</description>
        </group>
        <group group_id="E2">
          <title>MK-0954A (L100/H12.5) Double Blind Period (Period 1)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5)</description>
        </group>
        <group group_id="E3">
          <title>L50/H12.5→L100/H12.5 Open Label (Period 2)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)</description>
        </group>
        <group group_id="E4">
          <title>L100/H12.5→L100/H12.5 Open Label (Period 2)</title>
          <description>One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="131"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E3" events="36" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E4" events="34" subjects_affected="27" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

